173 related articles for article (PubMed ID: 35548776)
1. Tumor Suppressor Role and Clinical Significance of the
Liang YX; Liang YK; Zou ZH; Zhuo YJ; Ye JH; Zhu XJ; Cai ZD; Lin ZY; Mo RJ; Wu SL; Zhang YQ; Zhong WD
Dis Markers; 2022; 2022():8724035. PubMed ID: 35548776
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
6. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
[TBL] [Abstract][Full Text] [Related]
7. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
Avgeris M; Stravodimos K; Fragoulis EG; Scorilas A
Br J Cancer; 2013 Jun; 108(12):2573-81. PubMed ID: 23703249
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.
Bi XC; Liu JM; Zheng XG; Xian ZY; Feng ZW; Lou YX; Zhong WD; Wu CL
Clin Invest Med; 2011 Dec; 34(6):E358. PubMed ID: 22129926
[TBL] [Abstract][Full Text] [Related]
9. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
10. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
11. Periostin: a promising target of therapeutical intervention for prostate cancer.
Sun C; Zhao X; Xu K; Gong J; Liu W; Ding W; Gou Y; Xia G; Ding Q
J Transl Med; 2011 Jun; 9():99. PubMed ID: 21714934
[TBL] [Abstract][Full Text] [Related]
12. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
13. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
[TBL] [Abstract][Full Text] [Related]
15. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
16. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of YTHDC2 contributes to the progression of prostate cancer and predicts poor outcomes in patients with prostate cancer.
Song J; You G; Yin X; Zhu G; Wang W; Yu Y; Zhu J
J Biochem Mol Toxicol; 2023 Apr; 37(4):e23308. PubMed ID: 36644951
[TBL] [Abstract][Full Text] [Related]
18. [miR-129 in the diagnosis, treatment and prediction of clinical prognosis of prostate cancer].
Zhao XD; Tang ZL; Wang ZH; Dong J; Xu S
Zhonghua Nan Ke Xue; 2022 Nov; 28(11):996-1005. PubMed ID: 37846115
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]